Showing results (161-170 of 259) with videos related to
Sort By:
Pageof 26
The New England Journal of Medicine|April 9, 2015
Ibrutinib in previously treated Waldenström's macroglobulinemiaSteven P Treon, Christina K Tripsas, Kirsten Meid, et al.Open Forum Infectious Diseases|May 2, 2022
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE StudySteven E Coutre, Christopher Barnett, Olayemi Osiyemi, et al.Seminars in Oncology|April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRobert A Kyle, Steven P Treon, Raymond Alexanian, et al.Blood|November 16, 2002
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signalingYu-Tzu Tai, Klaus Podar, Nicholas Mitsiades, et al.Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.Cancer Research|October 30, 2003
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ron T Bronson, et al.Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.British Journal of Haematology|July 30, 2016
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomesJosephine M Vos, Joshua Gustine, Helmut G Rennke, et al.Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemiaSteven P Treon, Mark Hansen, Andrew R Branagan, et al.Pageof 26